Compare AOMR & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOMR | HELP |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.7M | 249.0M |
| IPO Year | 2019 | N/A |
| Metric | AOMR | HELP |
|---|---|---|
| Price | $9.07 | $5.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $11.08 | ★ $51.50 |
| AVG Volume (30 Days) | 60.4K | ★ 1.3M |
| Earning Date | 05-05-2026 | 02-13-2026 |
| Dividend Yield | ★ 14.33% | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.38 | N/A |
| P/E Ratio | $4.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.96 | $4.29 |
| 52 Week High | $10.21 | $8.55 |
| Indicator | AOMR | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 63.87 | 52.56 |
| Support Level | $8.64 | $4.40 |
| Resistance Level | $9.22 | $8.55 |
| Average True Range (ATR) | 0.18 | 0.39 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 88.21 | 54.21 |
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.